Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COVID Funding: White House Pleads For Emergency Extension As ‘Runway’ To Commercial Market

Executive Summary

Biden administration warns that additional oral antivirals may not be purchased if Congress does not provide $22.5bn emergency funding for COVID response, imperiling the new Test to Treat initiative and other programs.

You may also be interested in...

US Advanced Purchases For COVID Drugs A Model Post-Pandemic? Not Likely, Manufacturers Warn

Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.

What To Expect If Republicans Regain Majority: More Executive Actions, Focus On Costs

Lobbyists discuss what will happen with the healthcare agenda if Republicans retake the House in the mid-term elections and the prospects for passing a prescription drug pricing bill before then.

Test To Treat Tug-of-War: Pharmacy, Physician Groups Each Have Concerns With Biden COVID Plan

Community pharmacists say widespread implementation of Biden’s rapid pill dispensing initiative necessitates allowing pharmacists to prescribe Paxlovid and molnupiravir. But AMA worries that even clinic-based prescribing puts patients at risk because it bypasses primary care doctors.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts